| LEGEND BIOTECH SP.ADS/2 |
| USA |
| Gesundheit |
| US52490G1022 / A2P5AH |
| 9LB (Frankfurt) / LEGN (NASDAQ) |
| FRA:9LB, ETR:9LB, 9LB:GR, NASDAQ:LEGN |
| - |
| https://www.legendbiotech.. |
|
Legend Biotech Corporation develops, manufactures, and commercializes chimeric antigen receptor T-cell (CAR-T) therapies for oncology and other serious diseases. The company's flagship product is CARVYKTI, a BCMA-targeted CAR-T cell therapy for relap..
>Volltext.. |
| 3052.17 Mio. EUR |
| 2588.78 Mio. EUR |
| 893.78 Mio. EUR |
| -92.43 Mio. EUR |
| -257.8 Mio. EUR |
| -1.4 EUR |
| 358.4 Mio. EUR |
| 781.33 Mio. EUR |
| -167.9 Mio. EUR |
| 1.49 |
| 64.66% |
| -68.01% |
| - |
| - |
| - |
| LEGEND BIOTECH |
| 05.04.26 |
|
||||
|